Literature DB >> 9264398

Sezary cell-like leukemia with atypical immunophenotype.

M Orero, A Miguel-Sosa, A Miguel-Garcia, F Tarín, K McCarty, F Carbonell, E Matutes, M Sanchez.   

Abstract

We describe the clinical and laboratory features of an unusual case with Sezary cell-like leukemia. Clinical manifestations were: anemia (Hb 9.4 g/dl), severe thrombocytopenia (5 x 10(9)/l), lymphocytosis (43 x 10(9)/l) and splenomegaly. There was no lymphadenopathy, hepatomegaly or skin lesions. Bone marrow trephine showed diffuse infiltration by atypical lymphoid cells. By ultrastructural analysis the cells were small to medium-size lymphocytes with nuclear features identical to Sezary cells. Immunophenotyping showed that most peripheral blood mononuclear cells were negative with B lymphoid, myeloid, and stem cell-associated markers and were also negative with most T lymphoid markers (CD2, CD4, membrane/cytoplasmic CD3, CD5 and CD8). However, they were positive with CD38 (70%), CD7 (25%) and TIA-2 (25%). Molecular analysis showed a clonal rearrangement of the TCR beta and gamma chain genes. The patient was initially treated with vincristine, doxorubicin and asparaginase and then with six cycles of CHOP, achieving a complete remission and remaining free of disease 22 months from diagnosis. Aberrant immunophenotypes are not frequent in primary T cell leukemias. This is the first case of a rare type of T cell neoplasm, Sezary cell-like leukemia, in which cells lacked most of the T cell-associated antigens.

Entities:  

Mesh:

Year:  1997        PMID: 9264398     DOI: 10.1038/sj.leu.2400709

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  1 in total

1.  CD38 Expression by Circulating and Skin-Infiltrating Lymphocytes from Sezary Syndrome Patients: A Flow Cytometry and Immunohistochemistry Study.

Authors:  Pietro Quaglino; Mauro Novelli; Paolo Fava; Erika Ortolan; Chiara Astrua; Luca Tonella; Carlo Francesco Tomasini; Rebecca Senetta; Simone Ribero; Renata Ponti; Maria Teresa Fierro; Ada Funaro
Journal:  Dis Markers       Date:  2022-02-24       Impact factor: 3.434

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.